Comparative Pharmacology
Head-to-head clinical analysis: MYCITRACIN versus PRED G.
Head-to-head clinical analysis: MYCITRACIN versus PRED G.
MYCITRACIN vs PRED-G
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MYCITRACIN is a combination of bacitracin and neomycin, which are aminoglycoside antibiotics. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan subunits. Neomycin binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
Prednisolone acetate is a glucocorticoid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis; gentamicin sulfate is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to 30S ribosomal subunit.
500 mg orally every 6 hours
1 drop of the ophthalmic suspension (containing prednisolone acetate 1% and gentamicin sulfate 0.3%) into the affected eye(s) every 2-4 hours during the day, then taper as clinical signs improve. For severe disease, 1 drop every hour initially.
None Documented
None Documented
Terminal elimination half-life is 2–3 hours in adults with normal renal function. Prolonged significantly in renal impairment (up to 24–48 hours in anuria).
The terminal elimination half-life of gentamicin (the active component) is approximately 2–3 hours in adults with normal renal function. In neonates, half-life is prolonged to 5–11 hours. The immunosuppressive component (prednisolone) has a half-life of 2–4 hours.
Primarily renal (glomerular filtration and tubular secretion); >90% of dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<5%).
Renal excretion accounts for approximately 70% of elimination, with the remainder as unchanged drug in feces (20%) and biliary excretion (10%).
Category C
Category C
Antibiotic Combination
Ophthalmic Corticosteroid/Antibiotic Combination